Kumquat Biopharma

Kumquat Biopharma is a clinical-stage biotechnology company focused on the discovery and development of first-in-class small molecule drugs for cancer treatment. Founded in 2019 by the veteran team behind Wellspring Biosciences, the company utilizes a proprietary platform to target complex biological pathways in immuno-oncology. Their research aims to convert "cold" tumors into "hot" tumors, thereby enhancing the body's natural immune response against cancer cells. Kumquat has secured significant funding and established a multi-billion dollar strategic collaboration with Eli Lilly to advance its pipeline. The company's lead candidate, KQB-101, is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors. Headquartered in San Diego, Kumquat continues to leverage its expertise in structural biology and medicinal chemistry to address "hard-to-drug" targets.